Literature DB >> 11504542

Expression of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor monocistronic and bicistronic transcripts in primary effusion lymphomas.

R G Nador1, L L Milligan, O Flore, X Wang, L Arvanitakis, D M Knowles, E Cesarman.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) encodes a G protein-coupled receptor (vGPCR) in open reading frame (ORF) 74, which is homologous to human chemokine receptors. KSHV vGPCR is constitutively active and induces VEGF-mediated angiogenesis. Previous studies have shown that ORF 74 is transcribed as part of a bicistronic message containing ORF K14 upstream of ORF 74, with an early lytic pattern of expression. We have now extended these studies by analyzing three different KSHV-positive primary effusion lymphoma (PEL) cell lines and three PEL clinical samples. In addition, we have identified another less abundant monocistronic transcript containing only ORF 74. Both transcripts were identified at low but similar levels in two PEL clinical samples. We evaluated the degree of sequence and functional conservation of ORF74 in three additional PELs and two KS clinical specimens, demonstrating complete identity at the amino acid level among all isolates. While it is expressed as an early lytic transcript in PEL cell lines, in primary clinical PEL samples transcription of KSHV vGPCR can be readily detected. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11504542     DOI: 10.1006/viro.2001.1016

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  32 in total

1.  The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells.

Authors:  Mark Cannon; Nicola J Philpott; Ethel Cesarman
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  KSHV G protein-coupled receptor inhibits lytic gene transcription in primary-effusion lymphoma cells via p21-mediated inhibition of Cdk2.

Authors:  Mark Cannon; Ethel Cesarman; Chris Boshoff
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Cohesins localize with CTCF at the KSHV latency control region and at cellular c-myc and H19/Igf2 insulators.

Authors:  William Stedman; Hyojeung Kang; Shu Lin; Joseph L Kissil; Marisa S Bartolomei; Paul M Lieberman
Journal:  EMBO J       Date:  2008-01-24       Impact factor: 11.598

Review 4.  Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.

Authors:  Qiliang Cai; Suhbash C Verma; Jie Lu; Erle S Robertson
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

5.  Mechanism of glycyrrhizic acid inhibition of Kaposi's sarcoma-associated herpesvirus: disruption of CTCF-cohesin-mediated RNA polymerase II pausing and sister chromatid cohesion.

Authors:  Hyojeung Kang; Paul M Lieberman
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

Review 6.  How virus persistence can initiate the tumorigenesis process.

Authors:  Simone Avanzi; Gualtiero Alvisi; Alessandro Ripalti
Journal:  World J Virol       Date:  2013-05-12

7.  Expression of the Antisense-to-Latency Transcript Long Noncoding RNA in Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  Jason M Schifano; Kathleen Corcoran; Hemant Kelkar; Dirk P Dittmer
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

8.  Quantitative analysis of the bidirectional viral G-protein-coupled receptor and lytic latency-associated nuclear antigen promoter of Kaposi's sarcoma-associated herpesvirus.

Authors:  Isaac B Hilton; Dirk P Dittmer
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

9.  Induction of angiogenic chemokine CCL2 by human herpesvirus 8 chemokine receptor.

Authors:  Young Bong Choi; John Nicholas
Journal:  Virology       Date:  2009-12-09       Impact factor: 3.616

10.  RBP-J (CSL) is essential for activation of the K14/vGPCR promoter of Kaposi's sarcoma-associated herpesvirus by the lytic switch protein RTA.

Authors:  Yuying Liang; Don Ganem
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.